Our Approach
At Enliven Therapeutics, our primary focus lies in targeting opportunities emerging from validated biology, utilizing differentiated chemistry and compound design, and instilling disciplined clinical trial design and regulatory strategy to address cancer’s unmet needs.
The Enliven Difference
We strive to improve survival and overall well-being for cancer patients. Despite the advancement of precision medicine in oncology, a significant unmet need remains for the majority of cancer patients for whom no targeted therapies exist or whose cancer has developed resistance to currently available targeted treatments. For those on existing therapies, poor drug tolerability can both limit and diminish gains in survival. Additionally, efficacy-related challenges like drug resistance and disease recurrence have emerged, hindering patients’ quality of life and longevity.
We aim to address existing and emerging unmet needs with a precision oncology approach that will enhance the lives of cancer patients. Our drug candidates are designed to address issues such as tolerability, combinability, resistance, and disease escape through brain metastases. We plan to efficiently advance therapies to patients in need by reviewing and incorporating regulatory and clinical development strategies early in R&D.
Best-In-Class & First-in-Class
Our primary focus lies in opportunities emerging from validated biology, where we believe we can improve upon the standard of care. Our science addresses the challenges of existing therapies–tolerability, combinability and emerging issues like resistance and disease progression–with a novel precision oncology approach.
Unique Insights Applied to Validated Biology
Utilizing our deep understanding of the fundamental genetic alterations in oncology and insights from real-world market research, we can efficiently pursue novel approaches to target emerging and clinically-validated oncogenic drivers and signaling nodes.
Not All Chemistry is Created Equal
Our focus on the chemical space we deeply understand enables us to rapidly synthesize advanced libraries of diverse drug-like compounds for our selected target opportunities in a highly efficient discovery process that is difficult for companies with larger pipelines and broader focus to match.
Disciplined Clinical and Regulatory Strategy
Our development efforts utilize biomarker-enriched patient selection to build a high-quality dataset to test efficacy early and provide opportunities to enable future trials in earlier lines of therapy.